Outcomes of Blood Flow Restriction Therapy as an Adjunct to Standard Rehabilitation Following Anterior Cruciate Ligament Reconstruction: A Prospective Observational Cohort Study.
{"title":"Outcomes of Blood Flow Restriction Therapy as an Adjunct to Standard Rehabilitation Following Anterior Cruciate Ligament Reconstruction: A Prospective Observational Cohort Study.","authors":"Happy Gahlawat, Jaswant Kumar, Amit Hegde, Prashant Sharma, Himanshu Gupta, Deepak Joshi","doi":"10.13107/jocr.2026.v16.i10.8322","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Quadriceps weakness and muscle atrophy remain major challenges following anterior cruciate ligament (ACL) reconstruction. Blood flow restriction (BFR) therapy enables low-load resistance training and may enhance early rehabilitation outcomes. This study evaluated the clinical and radiological outcomes of adding BFR therapy to standard post-operative rehabilitation.</p><p><strong>Materials and methods: </strong>In this prospective observational cohort study, 40 patients (18-45 years) undergoing arthroscopic ACL reconstruction received standard rehabilitation supplemented with BFR therapy (60-80% limb occlusion pressure) from post-operative day 1 for 16 weeks. The primary outcome was quadriceps cross-sectional area (CSA) on magnetic resonance imaging. Secondary outcomes included Numeric Pain Rating Scale (NPRS), thigh girth, and Lysholm score. Paired t-tests were used for analysis.</p><p><strong>Results: </strong>Mean age was 28.25 ± 7.15 years, with 90% male. NPRS increased on post-operative day 1 (P < 0.0001) and significantly decreased thereafter (P ≤ 0.001). Lysholm scores improved from 70.57 ± 7.37 to 88.82 ± 5.38 (P < 0.0001), exceeding the minimal clinically important difference. Thigh girth remained unchanged (P > 0.05). Quadriceps CSA showed a non-significant reduction (approximately 6%; P = 0.123).</p><p><strong>Conclusion: </strong>BFR therapy is a safe and well-tolerated adjunct to standard ACL rehabilitation, associated with improved functional outcomes and pain while preserving muscle mass. Larger randomized controlled trials with longer follow-up are required to validate these findings.</p>","PeriodicalId":16647,"journal":{"name":"Journal of Orthopaedic Case Reports","volume":"16 10","pages":"485-492"},"PeriodicalIF":0.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646793/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Orthopaedic Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13107/jocr.2026.v16.i10.8322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Quadriceps weakness and muscle atrophy remain major challenges following anterior cruciate ligament (ACL) reconstruction. Blood flow restriction (BFR) therapy enables low-load resistance training and may enhance early rehabilitation outcomes. This study evaluated the clinical and radiological outcomes of adding BFR therapy to standard post-operative rehabilitation.
Materials and methods: In this prospective observational cohort study, 40 patients (18-45 years) undergoing arthroscopic ACL reconstruction received standard rehabilitation supplemented with BFR therapy (60-80% limb occlusion pressure) from post-operative day 1 for 16 weeks. The primary outcome was quadriceps cross-sectional area (CSA) on magnetic resonance imaging. Secondary outcomes included Numeric Pain Rating Scale (NPRS), thigh girth, and Lysholm score. Paired t-tests were used for analysis.
Results: Mean age was 28.25 ± 7.15 years, with 90% male. NPRS increased on post-operative day 1 (P < 0.0001) and significantly decreased thereafter (P ≤ 0.001). Lysholm scores improved from 70.57 ± 7.37 to 88.82 ± 5.38 (P < 0.0001), exceeding the minimal clinically important difference. Thigh girth remained unchanged (P > 0.05). Quadriceps CSA showed a non-significant reduction (approximately 6%; P = 0.123).
Conclusion: BFR therapy is a safe and well-tolerated adjunct to standard ACL rehabilitation, associated with improved functional outcomes and pain while preserving muscle mass. Larger randomized controlled trials with longer follow-up are required to validate these findings.